Epilepsy Foundation Awards $200,000 at 12th Annual Shark Tank Competition
BOWIE, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Epilepsy Foundation announced today it has awarded $200,000 in funding for two...
News
LUKE Awarded Top Workplaces 2024 Honor
ROCKLEDGE, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing for the...
Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract...
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
CNP-104 demonstrated potential efficacy across multiple immunological and clinical measurements, supporting its continued development as the first disease-modifying treatment for...
The Future is Now: Confronting Today’s Healthcare Challenges and Shaping Tomorrow’s Care at Empower
Inovalon’s Annual Data-Driven Summit Intersects Healthcare and Technology, Promising to Propel Meaningful Change Across the Care ContinuumBOWIE, Md., Sept. 30,...
Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization whose mission is to democratize...
Superluminal Medicines Announces Formation of Scientific Advisory Board
Multidisciplinary board members bring expertise in drug discovery, clinical development, computational life science, GPCRs and drug formulationBOSTON, Sept. 30, 2024...
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic...
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distressStudy results...
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA)...
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late...
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer’s Disease
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company...
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio...
BrightSpring Health Services, Inc. Welcomes Dr. Steve Miller to Board of Directors
LOUISVILLE, Ky., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider...
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected...
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage...
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
Clinical data demonstrated treatment with AGA2118 resulted in dose-dependent increases in bone mineral densityWOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE...